Cited by 286Breast Cancer Treatment StudiesCancer survivorship and careMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Open access

Cella, David, Fallowfield, Lesley J.·2008·Breast Cancer Research and Treatment

Open this paper in CoChat — free account

Abstract

In postmenopausal women with hormone receptor-positive early-stage breast cancer, the use of aromatase inhibitors (AIs) to suppress estrogen is associated with improved clinical outcomes compared with tamoxifen therapy. Women receiving such endocrine therapy may experience treatment-related side effects that negatively affect health-related quality of life (QoL) and adherence to therapy. In published clinical trials and in clinical practice, adverse events (AEs) constitute the main reason for nonadherence to endocrine treatment. Serious AEs are sometimes resolved by switching to a different agent, whereas other side effects can often be managed to allow patients to remain on therapy without sacrificing QoL. Across all adjuvant endocrine trials, regardless of the treatment received, vasomotor symptoms such as hot flashes are the most common side effects. Other frequently reported side effects, such as vaginal discharge, vaginal dryness, dyspareunia, and arthralgia, vary in prevalence between tamoxifen and AIs. Here we provide an overview of reported AEs of adjuvant endocrine therapy, focusing on those that are amenable to pharmacologic or nonpharmacologic management without treatment discontinuation. Also highlighted are specific management strategies that may improve patient QoL and thereby optimize adherence to therapy, which in turn might improve patient outcomes.

Integrity signals

Registry

Crossref · 10.1007/s10549-007-9548-1

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Drug-induced lupus erythematosus
Sarzi‐Puttini, P., Atzeni, F., Sarzi‐Puttini, P., Atzeni, F., CAPSONI, F., Sarzi‐Puttini, P., Atzeni, F., CAPSONI, F., Lubrano, E., Sarzi‐Puttini, P., et al. (2005) · Autoimmunity · doi:10.1080/08916930500285857 · Cited by 125
Retracted
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284 · cited 1×
“Conversely, the systemic estrogen deprivation that results from AI therapy in postmenopausal women can result in bone resorption and osteoporosis, with higher fracture rates [2, 4, 7].”
Background
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Self-citation
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
The Breast International Group (BIG) 1-98 Collaborative Group (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,584
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M. M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,116 · cited 3×
“005), suggesting inhibition of endometrial proliferation by the AI [7].”
BackgroundMethodInfluential
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Winer, E. P., Hudis, C. A., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R. D., Edge, S. B., Gralow, J. R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,026
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954 · cited 1×
“Loss of libido Better patient/physician communication Transdermal testosterone Shifren et al. [ 66 ]”
Background
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
Jin, Y., Desta, Z., Stearns, V., Ward, B. A., Ho, H., Lee, K.-H., Skaar, T. C., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951

Show all 83 references

Research works printed but not linked: 4

Taylor M, Rastelli A, Civitelli R et al (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. Abstract presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, TX
Thompson JN, Napoli N, Civitelli R et al (2006) Effects of dietary calcium vs. calcium supplements on estrogen metabolism and bone density. Osteoporos Int 17:S205 (abstract P696MO)
Plourde P, Locker G, Hoctin-Boes G et al (2005) Arthralgia in postmenopausal breast cancer patients on adjuvant endocrine therapy: a risk-benefit analysis. Poster presented at: 7th Annual Lynn Sage Breast Cancer Symposium; October 6–9 2005; Chicago, Illinois
Mok K, Mireskandari S, Juraskova I et al (2006) OVER (Olive oil Vaginal Exercises and Replens) Come. Psycho-Oncology 15:S332 (abstract 778)

Sorted by citations

Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007
Montazeri, A. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-32 · Cited by 773
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018
Mokhtari-Hesari, P., & Montazeri, A. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01591-x · Cited by 462
Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial
Mann, E., Smith, M. J., Hellier, J., Balabanovic, J. A., Hamed, H., Grunfeld, E. A., & Hunter, M. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70364-3 · Cited by 307
A Randomized Trial to Increase Physical Activity in Breast Cancer Survivors
Rogers, L. Q., Hopkins-Price, P. L., Vicari, S., Pamenter, R. W., Courneya, K. S., Markwell, S. J., Verhulst, S. J., Hoelzer, K. L., Naritoku, C., Jones, L., et al. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31818e0e1b · Cited by 220
Vasomotor Symptoms Across the Menopause Transition
Avis, N. E., Crawford, S. L., & Green, R. (2018) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2018.07.005 · Cited by 216
Relationship Between Deficits in Overall Quality of Life and Non–Small-Cell Lung Cancer Survival
Sloan, J. A., Zhao, X., Novotny, P. J., Wampfler, J. A., Garces, Y. I., Clark, M. M., & Yang, P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4631 · Cited by 183
“Perhaps, given their poor functioning, individuals with poor QOL demonstrate poor adherence to their medical treatment.(58,59) If a patient with lung cancer is not feeling well, optimistic, or motivated, it would seem possible that he or she may be less likely to keep medical appointments, attend treatment sessions, o…”
Background
Long‐term psychological benefits of cognitive‐behavioral stress management for women with breast cancer: 11‐year follow‐up of a randomized controlled trial
Stagl, J. M., Bouchard, L. C., Lechner, S. C., Blomberg, B. B., Gudenkauf, L. M., Jutagir, D. R., Glück, S., Derhagopian, R. P., Carver, C. S., & Antoni, M. H. (2015) · Cancer · doi:10.1002/cncr.29076 · Cited by 174
Non-hormonal interventions for hot flushes in women with a history of breast cancer
Gabriel Rada, G., Daniel Capurro, N., Tomás Pantoja, C., Corbalán, J., Moreno, G., Luz María Letelier, S., & Vera, C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004923.pub2 · Cited by 162
Breast cancer in young women and its impact on reproductive function
Hickey, M., Peate, M., Saunders, C. M., & Friedlander, M. L. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmn064 · Cited by 152
“Observational studies suggest that BRCA1 mutation carriers who have their first child at 30 years or older may have a reduced personal risk of breast cancer [43].”
Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor–Associated Arthralgia Syndrome
Morales, L., Pans, S., Verschueren, K., CALSTER, B. V., Paridaens, R., Westhovens, R., Timmerman, D., SMET, L. D., Vergote, I. B., Christiaens, M.-R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4005 · Cited by 150
Simple Strategies for Vaginal Health Promotion in Cancer Survivors
Carter, J., Goldfrank, D. J., & Schover, L. R. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01988.x · Cited by 138
The Physical Consequences of Gynecologic Cancer Surgery and Their Impact on Sexual, Emotional, and Quality of Life Issues
Carter, J., Stabile, C., Gunn, A., & Sonoda, Y. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12002 · Cited by 130
Physical Activity and Health Outcomes Three Months After Completing a Physical Activity Behavior Change Intervention: Persistent and Delayed Effects
Rogers, L. Q., Hopkins-Price, P. L., Vicari, S., Markwell, S. J., Pamenter, R. W., Courneya, K. S., Hoelzer, K. L., Naritoku, C., Edson, B., Jones, L., et al. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-1045 · Cited by 127
“Because of the association between adjuvant endocrine therapy and arthralgias (37) and the intervention focus on increasing weight bearing exercise (i.”
BackgroundResultInfluential
Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review
Lambert, L. K., Balneaves, L. G., Howard, A. F., & Gotay, C. C. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4561-5 · Cited by 134
“Limited treatment options, however, are available for managing AET-related side effects [68], which challenges clinicians in providing support to women experiencing symptoms.”
Background
Understanding tamoxifen adherence in women with breast cancer: A qualitative study
Moon, Z., Moss‐Morris, R., Hunter, M. S., & Hughes, L. D. (2017) · British Journal of Health Psychology · doi:10.1111/bjhp.12266 · Cited by 112
“Changes to mood and irritability are reported in 11% - 67% of patients taking tamoxifen (Cella & Fallowfield, 2008; Moon et al., 2016).”
Background
Sisters Peer Counseling in Reproductive Issues After Treatment (SPIRIT)
Schover, L. R., Rhodes, M. M., Baum, G. P., Adams, J. H., Jenkins, R., LEWIS, P. E., & Jackson, K. E. (2011) · Cancer · doi:10.1002/cncr.26139 · Cited by 115
“Premenopausal women who experience abrupt, treatment-related, premature ovarian failure have the greatest risk of developing such symptoms,(4,8,9) but women who are treated with aromatase inhibitors also experience severe sexual and menopausal complaints.(10) African American women may be particularly vulnerable to re…”
Background
Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer
Hickey, M., Saunders, C. M., Partridge, A. H., Santoro, N. F., Joffe, H., & Stearns, V. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn353 · Cited by 112
“These are likely to vary according to age, menopausal status and relationship factors as well as the nature of surgical and endocrine treatments [8].”
Background
Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed
Vijayvergia, N., & Denlinger, C. S. (2015) · Journal of Personalized Medicine · doi:10.3390/jpm5030243 · Cited by 117
“Though not well studied in cancer survivors, these benefits may be especially relevant in survivors on endocrine therapies that increase risk of osteoporosis [87].”
Background
Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer
Farias, A. J., & Du, X. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2807 · Cited by 109
Hormonal therapy in breast cancer: A model disease for the personalization of cancer care
Puhalla, S., Bhattacharya, S., & Davidson, N. E. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.003 · Cited by 105
“There are pharmacological and nonpharmacological solutions to these side effects that can alleviate these side effects, such as the use of venlafaxine or gabapentin for hot flashes (Cella and Fallowfield, 2008).”
Background
Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer
Brett, J., Fenlon, D., Boulton, M., Hulbert-Williams, N. J., Walter, F. M., Donnelly, P., Lavery, B., Morgan, A., Morris, C., & Watson, E. (2018) · European Journal of Cancer Care · doi:10.1111/ecc.12601 · Cited by 98
“AETs are known to have a significant side effect profile which can adversely affect quality of life and have previously been cited as barriers to continuing with treatment (Harrow et al, 2013; Morgan & Fenlon 2013; Fenlon et al, 2009; Cella & Fallowfield 2008).”
Background
Tamoxifen in men: a review of adverse events
Wibowo, E., Pollock, P. A., Hollis, N., & Wassersug, R. J. (2016) · Andrology · doi:10.1111/andr.12197 · Cited by 97
“Studies in women with breast cancer suggest that informing patients about treatment-related AEs can help adherence to treatment (Heisig et al., 2014) and better management of AEs (Cella & Fallowfield, 2008).”
Background
Management of genitourinary syndrome of menopause in breast cancer survivors: An update
López, D. M. L. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i2.71 · Cited by 99
Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors
Gambacciani, M., & Marco Levancini, A. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000761 · Cited by 95
Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue
Lester, J., Pahouja, G., Andersen, B. L., & Lustberg, M. B. (2015) · Journal of Personalized Medicine · doi:10.3390/jpm5020050 · Cited by 93
“The use of chemotherapy during the first year after diagnosis of breast cancer significantly increases the risk of CIOF [7,30–32].”
BackgroundInfluential
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)
Wagner, L. I., Zhao, F., Goss, P. E., Chapman, J. W., Shepherd, L. E., Whelan, T. J., Mattar, B. I., Bufill, J. A., Schultz, W. C., LaFrancis, I. E., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4713-2 · Cited by 91
“The discrepancy between clinician- and patient-rated treatment side effects has been previously documented with AI therapy-related symptoms [6, 15].”
Self-citation
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
Dent, S. F., Gaspo, R., Kissner, M., & Pritchard, K. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1351-3 · Cited by 90
Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review
Hurtado-de-Mendoza, A., Cabling, M. L., Lobo, T., Dash, C., & Sheppard, V. B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.03.006 · Cited by 79
Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)
Oberguggenberger, A., Michael, H., Sztankay, M. J., Meraner, V., Beer, B., Oberacher, H., Giesinger, J. M., Kemmler, G., Egle, D., Gamper, E., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1378-5 · Cited by 84
Acupuncture improves health-related quality-of-life (HRQoL) and sleep in women with breast cancer and hot flushes
Frisk, J., Källström, A.-C., Wall, N., Fredrikson, M. G., & Hammar, M. L. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1134-8 · Cited by 85
“This is partially due to endocrine therapy like tamoxifen, which may increase hot flushes [11], making patients stop their treatment prematurely [12].”
Background
Predicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention
Lin, J., Zhang, S. M., & Manson, J. E. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0380 · Cited by 83
Exercise in Clinical Cancer Care: A Call to Action and Program Development Description
Mina, D. S., Alibhai, S. M. H., Matthew, A., Guglietti, C. L., Steele, J. R., Trachtenberg, J., & Ritvo, P. G. (2012) · Current Oncology · doi:10.3747/co.19.912 · Cited by 81
The impact of age on changes in quality of life among breast cancer survivors treated with breast-conserving surgery and radiotherapy
Bantema-Joppe, E. J., de Bock, G. H., Iersel, M. W.-V., Busz, D. M., Ranchor, A., Langendijk, J. A., Maduro, J. H., & van den Heuvel, E. R. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.632 · Cited by 80
“The lack of change over time cannot be explained by the use of systemic treatment, resulting in vaginal dryness (Varras et al, 2003; Cella and Fallowfield, 2008) since we controlled for systemic treatment.”
Background
Physical Activity and Breast Cancer: A Qualitative Study on the Barriers to and Facilitators of Exercise Promotion from the Perspective of Health Care Professionals
Smith‐Turchyn, J., Richardson, J. A., Tozer, R. G., McNeely, M. L., & Thabane, L. (2016) · Physiotherapy Canada · doi:10.3138/ptc.2015-84 · Cited by 80
The influence of endocrine treatments for breast cancer on health-related quality of life
Buijs, C., de Vries, E. G. E., Mourits, M. J. E., & Willemse, P. H. B. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.001 · Cited by 80
Endocrine‐related quality of life in a randomized trial of exercise on aromatase inhibitor–induced arthralgias in breast cancer survivors
Baglia, M. L., Lin, I., Cartmel, B., Sanft, T. B., Ligibel, J. A., Hershman, D. L., Harrigan, M., Ferrucci, L. M., Li, F., & Irwin, M. L. (2019) · Cancer · doi:10.1002/cncr.32051 · Cited by 84
“Pharmacologic therapies, such as use of nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, glucosamine, and narcotic analgesics, also have been studied to alleviate pain from AI-induced arthralgias but may be contraindicated or ineffective.(29) A randomized trial of duloxetine in 299 patients with brea…”
Background
The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review
Chao, L.-F., Zhang, A. L., Liu, H., Cheng, M., Lam, H.-B., & Lo, S. K. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0533-8 · Cited by 78
Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
Khan, Q. J., O’Dea, A. P., & Sharma, P. (2010) · Journal of Oncology · doi:10.1155/2010/654348 · Cited by 75
“A possible biologic explanation of AIinduced musculoskeletal symptoms and their improvement with vitamin D supplementation is that reduction in joint estrogen levels may unmask subclinical Vitamin D deficiency.”
Background
Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease
Eisner, A., & Luoh, S. (2011) · Current Eye Research · doi:10.3109/02713683.2011.594202 · Cited by 79
Better exercise adherence after treatment for cancer (BEAT Cancer) study: Rationale, design, and methods
Rogers, L. Q., McAuley, E., Anton, P. M., Courneya, K. S., Vicari, S. K., Hopkins-Price, P. L., Verhulst, S. J., Mocharnuk, R. S., & Hoelzer, K. L. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.09.004 · Cited by 77
“The improvement in joint symptoms is of clinical importance because of the current lack of effective therapies for arthralgias related to breast cancer therapy [94] and additional research to confirm our findings is warranted.”
Breast Cancer Survivorship Issues
Stan, D. L., Loprinzi, C. L., & Ruddy, K. J. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.05.005 · Cited by 75
“Compared with tamoxifen, the AIs are slightly less likely to cause hot flashes.(9) In general, the symptoms that result from chemotherapy-induced menopause are more severe than those associated with natural menopause.”
Background
Sexual function in breast cancer patients: a prospective study from Iran
Harirchi, I., Montazeri, A., Bidokht, F. Z., Mamishi, N., & Zendehdel, K. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-20 · Cited by 72
Perceptions of Patients With Breast and Colon Cancer of the Management of Cancer-Related Pain, Fatigue, and Emotional Distress in Community Oncology
Smith, T. G., Troeschel, A. N., Castro, K. M., Arora, N., Stein, K., Lipscomb, J., Brawley, O. W., McCabe, R. M., Clauser, S. B., & Ward, E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01579 · Cited by 71
Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for breast cancer
Corter, A. L., Findlay, M. P. N., Broom, R. J., Porter, D. J. T., & Petrie, K. J. (2012) · British Journal of Health Psychology · doi:10.1111/bjhp.12003 · Cited by 69
“…numbers of women who are being prescribed adjuvant endocrine therapy for 5–10 years, and because of the strong association between reported side effects of adjuvant endocrine therapy and non-adherence to treatment (Cella & Fallowfield, 2008; Henry, Giles& Stearns, 2008; Pellegrini et al., 2009).”
Background
Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)
Barton, D. L., Shuster, L. T., Dockter, T., Atherton, P. J., Thielen, J. M., Birrell, S. N., Sood, R., Griffin, P. C., Terstriep, S. A., Mattar, B. I., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3960-9 · Cited by 69
“This treatment can add to the extent and severity of menopausal symptoms, particularly vaginal symptoms such as dryness and dyspareunia [3, 4].”
Background
Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial
von Blanckenburg, P., Schuricht, F., Albert, U., Rief, W., & Nestoriuc, Y. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-426 · Cited by 67
“Most frequently reported side effects of endocrine therapy are arthralgia, hot flushes, weight gain, mood swings, loss of libido and vaginal dryness [11,12].”
Background
Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
Lambert, L. K., Balneaves, L. G., Howard, A. F., Chia, S., & Gotay, C. C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4644-7 · Cited by 67
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
Cardoso, F., Parke, S., Brennan, D. J., Briggs, P., Donders, G. G. G., Panay, N., Mashhadi, N. H., Block, M. S., Caetano, C., Francuski, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415566 · Cited by 75
Impact of Depression on Treatment Adherence and Survival from Cancer
DiMatteo, M. R., & Haskard‐Zolnierek, K. B. (2010) · doi:10.1002/9780470972533.ch5 · Cited by 64
Contemporary Quality of Life Issues Affecting Gynecologic Cancer Survivors
Carter, J., Penson, R. T., Barakat, R. R., & Wenzel, L. B. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.11.001 · Cited by 63
Breast cancer patients’ experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis
Clancy, C., Lynch, J., O'Connor, P. M., & Dowling, M. (2019) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2019.101706 · Cited by 66
Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale
Hagen, K. B., Aas, T., Lode, K., Gjerde, J., Lien, E., Kvaløy, J. T., Lash, T. L., Søiland, H., & Lind, R. (2015) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2014.10.009 · Cited by 62
Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy
Shelby, R. A., Edmond, S. N., Wren, A. A., Keefe, F. J., Peppercorn, J. M., Marcom, P. K., Blackwell, K. L., & Kimmick, G. G. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2269-1 · Cited by 76
“Menopausal symptoms, such as hot flushes, night sweats, and vaginal symptoms, are common side effects of all adjuvant endocrine therapy medications [11].”
Background
Gender and Sexual Labor Near the End of Life: Advanced Breast Cancer and Femininity Norms
McClelland, S. I. (2017) · Women s Reproductive Health · doi:10.1080/23293691.2017.1276367 · Cited by 61
Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients
Pfeiler, G., Glatz, C., Königsberg, R., Geisendorfer, T., Fink-Retter, A., Kubista, E., Singer, C. F., & Seifert, M. (2011) · Climacteric · doi:10.3109/13697137.2010.529967 · Cited by 60
Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research
Liew, J. R., Christensen, A. J., & de Moor, J. S. (2014) · Journal of Cancer Survivorship · doi:10.1007/s11764-014-0374-2 · Cited by 59
“Alternatively, tamoxifen use may be accompanied by gynecological symptoms such as vaginal bleeding and discharge [12].”
Background
Factors related to the experience of menopausal symptoms in women prescribed tamoxifen
Moon, Z., Hunter, M. S., Moss-Morris, R. E., & Hughes, L. D. (2016) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2016.1216963 · Cited by 59
“This may be because some women who experienced negative side effects discontinued treatment and were removed from the RCTs.”
BackgroundResultInfluential
Effectiveness of Internet-based interventions in managing chemotherapy-related symptoms in patients with cancer: a systematic literature review
Moradian, S., Voelker, N., Brown, C., Liu, G., & Howell, D. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3900-8 · Cited by 64
“Cancer Introduction Major advances in different cancer treatment modalities have been made, and people are now living longer with cancer [1, 2].”
Background
Naringenin has a chemoprotective effect in MDA‑MB‑231 breast cancer cells via inhibition of caspase‑3 and ‑9 activities
Wang, R., Wang, J., Dong, T., Shen, J., Gao, X., & Zhou, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9704 · Cited by 57
Retracted
Self-reported side effects of breast cancer treatment: a cross-sectional study of incidence, associations, and the influence of exercise
Gho, S. A., Steele, J. R., Jones, S. C., & Munro, B. J. (2013) · Cancer Causes & Control · doi:10.1007/s10552-012-0142-4 · Cited by 59
“Similar to improvements in shoulder limitations, these effects go beyond exclusively physical benefits, with cardio-respiratory improvements having also been positively correlated with QOL scores in a breast cancer cohort [43].”
BackgroundInfluential
Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer
Rosenberg, S. M., Stanton, A. L., Petrie, K. J., & Partridge, A. H. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0007 · Cited by 61
Naringenin Enhances the Anti-Cancer Effect of Cyclophosphamide against MDA-MB-231 Breast Cancer Cells Via Targeting the STAT3 Signaling Pathway
Noori, S., Tavirani, M. R., Deravi, N., Rabbani, M. I. M., & Zarghi, A. (2020) · Iranian journal of pharmaceutical research · doi:10.22037/ijpr.2020.113103.14112 · Cited by 54
Risks and Benefits of Physical Activity among Breast Cancer Survivors who have Completed Treatment
Schmitz, K. H., & Speck, R. M. (2010) · Women s Health · doi:10.2217/whe.10.1 · Cited by 57
“The most common symptoms reported are arthralgias (muscle pain) and hot flashes, which have been reported to occur in 35% of women taking aromatase inhibitors [23].”
Background
Aromatase inhibitor therapy and hair loss among breast cancer survivors
Gallicchio, L. M., Calhoun, C., & Helzlsouer, K. J. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2744-2 · Cited by 51
Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women
Collin, L. J., Cronin-Fenton, D. P., Ahern, T. P., Goodman, M. G., McCullough, L. E., Waller, L. A., Kjærsgaard, A., Damkier, P., Christiansen, P., Ejlertsen, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3974 · Cited by 55
“, hot flashes, nausea, fatigue, arthralgia, vaginal bleeding, and fractures) that can affect a patient’s choice to continue therapy (17, 18).”
Background
Contemporaneous symptom networks and correlates during endocrine therapy among breast cancer patients: A network analysis
Jing, F., Zhu, Z., Qiu, J., Tang, L., Xu, L., Xing, W., & Hu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1081786 · Cited by 52
“Endocrine therapy-related symptoms (ESs) are defined as treatment-related side effects experienced by women receiving endocrine therapy that negatively affect health-related quality of life and adherence to therapy (9).”
BackgroundResultInfluential
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
Fallowfield, L. J., Kilburn, L., Langridge, C., Snowdon, C. F., Bliss, J. M., & Coombes, R. C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.43 · Cited by 50
“Examples include anxiety and depression or gynaecological symptoms such as vaginal dryness or discharge and irritation associated with dyspareunia (Cella and Fallowfield, 2008).”
BackgroundSelf-citation
Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study
Bluethmann, S. M., Murphy, C. C., Tiro, J. A., Mollica, M. A., Vernon, S. W., & Bartholomew, L. K. (2017) · Oncology nursing forum · doi:10.1188/17.onf.e101-e110 · Cited by 50
Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
Güth, U., Myrick, M. E., Schötzau, A., Kilic, N., & Schmid, S. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1668-y · Cited by 51
“As stated by other authors, a change in therapy may be an effective strategy to improve patient persistence and adherence [ 2 , 34].”
BackgroundInfluential
The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review
Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D. L., & Macpherson, I. R. (2022) · The Breast · doi:10.1016/j.breast.2022.04.010 · Cited by 53
“The most frequently used validated measures were the Breast Cancer Prevention Trial (BCPT) symptom checklist [21,38,54,56,74,77,92], Centre for Epidemiologic Studies – Depression (CES-D) [37,43,54,56,64], Hospital Anxiety and Depression Scale (HADS) [15,32,34,56,66,74,88] and the Brief Pain…”
Effect of Expressive Writing Intervention on Health Outcomes in Breast Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Zhou, C., Wu, Y., An, S., & Li, X. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131802 · Cited by 48
Safety of herbal medicinal products in women with breast cancer
Roberts, H. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.02.010 · Cited by 48
Symptom Clusters in Women With Breast Cancer During the First 18 Months of Adjuvant Therapy
Li, H., Sereika, S. M., Marsland, A. L., Conley, Y. P., & Bender, C. M. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.10.002 · Cited by 47
Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment: who benefits and how does it work?
Chilcot, J., Norton, S., & Hunter, M. S. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.01.007 · Cited by 45
“Hormone replacement therapy is generally contraindiated because it can increase the likelihood of recurrence, and, f left untreated, HFNS can reduce adherence to endocrine therpy [4,5].”
Background
Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial
Page, A., Verbakel, J. Y. J., Verhaeghe, J., Latul, Y. P., Housmans, S., & Deprest, J. A. (2022) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17335 · Cited by 45
Role of the general practitioner during the active breast cancer treatment phase: an analysis of health care use
Roorda, C., de Bock, G. H., van der Veen, W. J., Lindeman, A., Jansen, L., & van der Meer, K. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1133-9 · Cited by 44
“For example, patients may experience psychosocial distress and treatment-related side effects that negatively affect their health-related quality of life and adherence to adjuvant therapies [9–11].”
Background
A prospective model of care for breast cancer rehabilitation: Bone health and arthralgias
Winters‐Stone, K. M., Schwartz, A. L., Hayes, S. C., Fabian, C. J., & Campbell, K. L. (2012) · Cancer · doi:10.1002/cncr.27465 · Cited by 43
Plants Used for the Traditional Management of Cancer in the Eastern Cape Province of South Africa: A Review of Ethnobotanical Surveys, Ethnopharmacological Studies and Active Phytochemicals
Sagbo, I. J., & Otang-Mbeng, W. (2021) · Molecules · doi:10.3390/molecules26154639 · Cited by 44
“Some side effects reported in some men who use hormone therapy for the treatment of prostate cancer include nausea, fatigue, diarrhea, hot flashes and loss of interest in or ability to have sex [33] while the reported side effects in women who use hormone therapy for the treatment of breast cancer include loss of inte…”
Background
The Influence of Breast Cancer Treatment on the Occurrence of Hot Flashes
Savard, M., Savard, J., Quesnel, C., & Ivers, H. (2008) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2008.04.010 · Cited by 43
A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy
Bell, R. J., Rizvi, F., Islam, R. M., & Davis, S. R. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001052 · Cited by 43
Optimizing expectations about endocrine treatment for breast cancer: Results of the randomized controlled psy-breast trial
Mora, M. C. S., Pan, Y., Heisig, S. R., von Blanckenburg, P., Rief, W., Witzel, I., Albert, U., & Nestoriuc, Y. (2020) · Clinical Psychology in Europe · doi:10.32872/cpe.v2i1.2695 · Cited by 45
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort
Castel, L. D., Hartmann, K. E., Mayer, I. A., Saville, B. R., Alvarez, J., Boomershine, C. S., Abramson, V. G., Chakravarthy, A. B., Friedman, D. L., & Cella, D. F. (2013) · Cancer · doi:10.1002/cncr.28016 · Cited by 43
“001) Black, non-Hispanic 22 (8) 19 (11) 3 (3) Hispanic 3 (1) 2 (1) 1 (1) Other 2 (1) 1 (1) 1 (1) Missing/unknown/refused 10 (4) 5 (3) 5 (5) Married or partnered, n (%) 171 (67) 105 (62) 66 (76) 5.”
Self-citation
Estrogen-Receptor-Positive Breast Cancer in Postmenopausal Women: The Role of Body Composition and Physical Exercise
Dimauro, I., Grazioli, E., Antinozzi, C., Duranti, G., Arminio, A., Mancini, A., Greco, E. A., Caporossi, D., Parisi, A., & Luigi, L. D. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18189834 · Cited by 44
Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial
Mohammadinejad, P., Arya, P., Esfandbod, M., Kaviani, A., Najafi, M., Kashani, L., Zeinoddini, A., Emami, S. A., & Akhondzadeh, S. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015592215 · Cited by 39
“These drugs are used as first-line analgesics in cancer patients with bone metastasis, and they are also administrated routinely for pain relief in breast cancer patients with arthralgia resulting from the use of aromatase inhibitors.(8,9) 592215 AOPXXX10.”
Background
Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status
Farias, A. J., & Du, X. L. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0280 · Cited by 40
Nonhormonal Management of Hot Flashes for Women on Risk Reduction Therapy
Sideras, K., & Loprinzi, C. L. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0086 · Cited by 39
Does depression decrease the moderating effect of self‐efficacy in the relationship between illness perception and fear of progression in breast cancer?
Shim, E., Lee, J. W., & Min, Y. H. (2017) · Psycho-Oncology · doi:10.1002/pon.4532 · Cited by 37
“Persisting somatic symptoms such as menopausal symptoms, which are common side effects of the AET medications [15], might be interpreted as an indicator of cancer recurrence, increasing FOP [16].”
Oncology providers’ perspectives on endocrine therapy prescribing and management
Wheeler, S., Roberts, M., Bloom, D., Reeder-Hayes, K., Espada, M., Peppercorn, J., Golin, C., & Earp, J. A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s95594 · Cited by 31
“…individual patient), 18,19 tailoring risk communication 20 and side effects management to better fit with the individual patient’s experience, 21,22 and consolidating evidence-based information about effective management of ET-related side effects, including pharmacological and…”
Mind-body interventions for vasomotor symptoms in healthy menopausal women and breast cancer survivors. A systematic review
Stefanopoulou, E., & Grunfeld, E. A. (2017) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2016.1235147 · Cited by 35
“Moreover, HFNS can last for several years, which can reduce treatment adherence [9].”
Background
Menopausal symptoms in breast cancer survivors: management update
Cusack, L., Brennan, M. E., Baber, R., & Boyle, F. M. (2012) · British Journal of General Practice · doi:10.3399/bjgp13x660977 · Cited by 35
Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women
Hammarström, M., Gabrielson, M., Crippa, A., Discacciati, A., Eklund, M., Lundholm, C., Bäcklund, L. M., Wengström, Y., Borgquist, S., Bergqvist, J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02293-z · Cited by 35
“Vasomotor and vaginal symptoms are well-established side effects of tamoxifen [9, 11].”
BackgroundResult
Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data
Farias, A. J., Wu, W.-H., & Du, X. L. (2018) · BMC Cancer · doi:10.1186/s12885-018-5121-z · Cited by 35
Antiproliferative and apoptosis induction of cucurbitacin-type triterpenes from Ibervillea sonorae
Moreno, H. T., Velázquez, C. A., Garibay‐Escobar, A., Curini, M., Marcotullio, M. C., & Robles‐Zepeda, R. E. (2015) · Industrial Crops and Products · doi:10.1016/j.indcrop.2015.09.055 · Cited by 32
The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis
Jackson, C. H., Freeman, A. L. J., Szlamka, Z., & Spiegelhalter, D. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246441 · Cited by 35
Complementary and alternative medicine for natural and treatment-induced vasomotor symptoms: An overview of systematic reviews and meta-analyses
Guo, P., Li, P., Zhang, X., Liu, N., Wang, J., Chen, D., Sun, W., & Zhang, W. (2019) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2019.07.007 · Cited by 32
Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010
Dusetzina, S. B., Alexander, G. C., Freedman, R. A., Huskamp, H. A., & Keating, N. L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2330-z · Cited by 31
“Because treatment-related side effects of endocrine therapies may impact adherence [40], and untreated depression is associated with treatment non-adherence, poorer quality of life and worse health outcomes for patients with cancer [27, 41, 42], it is important for patients to continue to receive pharmacologic and non…”
Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines
Diller, M., Schüler, S., Buchholz, S., Lattrich, C., Treeck, O., & Ortmann, O. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.01.004 · Cited by 31
The Effectiveness of Group-based Self-management Programmes to Improve Physical and Psychological Outcomes in Patients with Cancer: a Systematic Review and Meta-analysis of Randomised Controlled Trials
Smith‐Turchyn, J., Morgan, A. R., & Richardson, J. A. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.10.003 · Cited by 32
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy
Gallicchio, L. M., MacDonald, R., Wood, B., Rushovich, E., & Helzlsouer, K. J. (2011) · Climacteric · doi:10.3109/13697137.2011.620658 · Cited by 31

Authors: Cella, D., & Fallowfield, L. J.
Affiliations: Northwestern University (US)
Brighton and Sussex Medical School (GB)
Corresponding author: Cella, David
ORCID: Cella, David
Fallowfield, Lesley J.
Venue: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Published: 2007-09-18
Volume: 107
Issue: 2
Pages: 167-180
ISSN: 0167-6806 (ISSN-L)
1573-7217
DOI: 10.1007/s10549-007-9548-1
OpenAlex: W2034100757
Cited by: 286
References: 83
Citations by year: 2026: 9 · 2025: 17 · 2024: 16 · 2023: 22 · 2022: 20 · 2021: 17 · 2020: 14 · 2019: 16 · 2018: 15 · 2017: 19 · 2016: 17 · 2015: 15 · 2014: 9 · 2013: 14 · 2012: 17
FWCI: 0.88
Type: journal article
Language: en
Open access: green
figshare.com
Licence: cc-by
www.springer.com/tdm (tdm)
Locations: Breast Cancer Research and Treatment (publishedVersion)
PubMed (publishedVersion)
Sussex Research Online (University of Sussex) (submittedVersion)
Figshare (submittedVersion, cc-by)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: breast cancer, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, treatment-related adverse events, medication adherence, health-related quality of life, vasomotor symptoms, hot flashes, vaginal dryness, dyspareunia, joint pain, adverse event management, hormone receptor-positive breast cancer
MeSH terms: Aromatase, Breast Neoplasms, Clinical Trials as Topic, Endocrine System, Female, Humans, Medical Oncology, Patient Compliance, Quality of Life, Surveys and Questionnaires, Tamoxifen, Treatment Outcome, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks